Core Insights - Danaher Corporation is recognized as a global leader in science and technology, particularly in Life Sciences, Diagnostics, and Biotechnology, outperforming competitors like Thermo Fisher Scientific and Agilent Technologies [1] - Analyst Vijay Kumar from Evercore ISI has set a price target of $254 for Danaher, suggesting a potential upside of 13.15% from its current stock price of $224.48 [1] Financial Performance - In the fourth quarter, Danaher reported an adjusted EPS of $2.23, slightly exceeding the Zacks Consensus Estimate of $2.22, with net sales of $6.84 billion, surpassing expectations of $6.79 billion, reflecting a year-over-year increase of 4.5% [2][6] - The Biotechnology segment saw a revenue increase of 9%, while Diagnostics profits rose by 14.3% [3] - For the full year 2025, Danaher achieved net revenues of $24.6 billion, a 3% increase from the previous year, with core sales growing by 2.5% in the fourth quarter [3][6] Future Outlook - Danaher has provided an optimistic earnings guidance for 2026, expecting low single-digit core sales growth in the first quarter and projecting an adjusted EPS between $8.35 and $8.50, indicating confidence in its growth trajectory [4] Stock Performance - Currently, Danaher's stock price is $224.48, reflecting a decrease of 4.78% or $11.28, with fluctuations between $223.09 and $235.07 on the day [5] - Over the past year, the stock reached a high of $242.80 and a low of $171, with a market capitalization of approximately $160.74 billion and a trading volume of 6.42 million shares [5]

Core Viewpoint - Danaher Corporation is experiencing strong financial performance, leading to a positive outlook from Evercore ISI, which has maintained an "Outperform" rating and raised its price target to $254 [1][6]. Financial Performance - Danaher reported fourth-quarter adjusted earnings per share (EPS) of $2.23, slightly exceeding the Zacks Consensus Estimate of $2.22 [2]. - Net sales for the quarter reached $6.84 billion, surpassing expectations of $6.79 billion, marking a 4.5% increase from the previous year [2]. - For the full year 2025, Danaher achieved net revenues of $24.6 billion, reflecting a 3% year-over-year increase [3]. Segment Performance - The Biotechnology segment saw a revenue surge of 9%, while the Diagnostics segment experienced a profit increase of 14.3% [3]. - The company projects low single-digit core sales growth in the first quarter of 2026, with adjusted EPS expected to range from $8.35 to $8.50 [3][6]. Stock Performance - Danaher's stock is currently priced at $223.995, reflecting a decrease of approximately 4.99% with a change of -$11.75 [4]. - The stock has fluctuated between a low of $223.09 and a high of $235.07 today, with a market capitalization of approximately $160.39 billion [4]. Market Dynamics - Foreign-currency translations positively impacted the quarter's results by 2.5%, while acquisitions and divestitures had a slight negative effect of 0.5% [5]. - The trading volume for the day is 5,105,026 shares on the NYSE, indicating active investor interest [5].

Group 1 - Danaher Corporation reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings of $2.23 per share and revenue of $6.84 billion, reflecting a year-over-year revenue increase of 4.5% [1] - The company's non-GAAP core revenue increased by 2.5%, driven by strong performance in bioprocessing [1] Group 2 - For the full year 2025, Danaher achieved adjusted earnings of $7.80 per share, marking a 4.5% growth, and revenue of $24.6 billion, which is a 3.0% increase from the previous year [2] - The company generated $6.4 billion in operating cash flow and $5.3 billion in non-GAAP free cash flow [2] Group 3 - Looking ahead, Danaher anticipates low-single-digit core revenue growth in the first quarter of 2026 [3] - For the full year, the company forecasts core revenue growth of 3% to 6% and adjusted earnings between $8.35 and $8.50 per share, with the midpoint slightly above the analyst consensus of $8.42 [3]

Core Insights - Danaher Corporation's (DHR) fourth-quarter 2025 adjusted earnings were $2.23 per share, exceeding the Zacks Consensus Estimate of $2.22, marking a 4% year-over-year increase [1] - The company reported net sales of $6.84 billion, surpassing the consensus estimate of $6.79 billion, with a year-over-year growth of 4.5% driven by strong performance across all segments [1] Financial Performance - DHR's core sales increased by 2.5% year over year in the quarter, with foreign-currency translations positively impacting sales by 2.5%, while acquisitions/divestitures had a negative impact of 0.5% [2] - For the full year 2025, DHR reported net revenues of $24.6 billion, a 3% increase year over year, and adjusted earnings of $7.80 per share, up 4.5% year over year [2] Segment Analysis - Life Sciences segment revenues reached $2.09 billion, up 2.5% year over year, exceeding the Zacks Consensus Estimate of $2.06 billion, with core sales increasing by 0.5% [3] - Diagnostics segment revenues totaled $2.72 billion, a 3% year-over-year increase, also surpassing the consensus estimate of $2.71 billion, with operating profit rising 14.3% year over year to $713 million [4] - Biotechnology segment revenues were $2.03 billion, up 9% year over year, exceeding the consensus estimate of $2.02 billion, with core sales increasing by 6% [5] Margin and Cost Structure - In Q4, Danaher's cost of sales increased by 8.5% year over year to $2.87 billion, while gross profit rose by 2% to $3.97 billion, resulting in a gross margin of 59.1%, slightly down from 59.5% in the previous year [6] - Operating profit increased by 5.4% year over year to $1.50 billion, although the operating margin declined to 19.1% from 20.4% in the year-ago quarter [7] Balance Sheet and Cash Flow - At the end of Q4, DHR had cash and equivalents of $4.62 billion, up from $2.08 billion at the end of 2024, while long-term debt increased to $18.4 billion from $15.5 billion [8] - The company generated net cash of $6.42 billion from operating activities in 2025, down from $6.69 billion in the previous year, with capital expenditures totaling $1.16 billion, a 17% decrease year over year [9] Future Outlook - For Q1 2026, Danaher expects low single-digit core sales growth year over year and anticipates adjusted earnings of $8.35-$8.50 per share [10][12] - The company projects a 3-6% increase in adjusted core sales for the full year 2026 [12]

Core Insights - Danaher reported revenue of $6.84 billion for the quarter ended December 2025, reflecting a year-over-year increase of 4.6% and a surprise of +0.64% over the Zacks Consensus Estimate of $6.79 billion [1] - The company's EPS for the quarter was $2.23, up from $2.14 in the same quarter last year, with an EPS surprise of +0.68% compared to the consensus estimate of $2.22 [1] Financial Performance Metrics - Organic sales growth was 2.5%, exceeding the average estimate of 1.8% from six analysts [4] - Total sales in the Biotechnology segment reached $2.03 billion, slightly above the five-analyst average estimate of $2.02 billion, representing a year-over-year increase of +8.8% [4] - Total sales in the Diagnostics segment were $2.72 billion, surpassing the estimated $2.7 billion, with a year-over-year change of +3.2% [4] - Life Sciences segment sales amounted to $2.09 billion, compared to the average estimate of $2.06 billion, reflecting a +2.6% year-over-year change [4] - Operating profit in the Biotechnology segment was $540 million, exceeding the estimated $535.78 million [4] - Operating profit for Diagnostics was $713 million, above the average estimate of $690.13 million [4] - Life Sciences operating profit reached $336 million, significantly higher than the average estimate of $258.78 million [4] - The stock has returned +2.2% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change, and currently holds a Zacks Rank 2 (Buy) [3]

Core Insights - Danaher Corporation reported a strong finish for 2025 with sales of $24.6 billion and a 2% core revenue growth, alongside an adjusted diluted EPS of $7.80, reflecting a 4.5% increase [3][4][7] - The company anticipates core revenue growth of 3% to 6% for 2026, with adjusted EPS guidance set between $8.35 and $8.50 [5][15] Financial Performance - For the fourth quarter, Danaher achieved sales of $6.8 billion and a 2.5% core revenue growth, with developed markets showing low single-digit growth and high-growth markets up mid-single digits [8] - Adjusted gross margin was reported at 58.2% and adjusted operating margin at 28.3%, both down 130 basis points year-over-year [9] Segment Performance - The biotechnology segment saw a core revenue increase of 6%, driven by high single-digit growth in bioprocessing [9][10] - Life sciences segment core revenue increased by 0.5%, with a modest recovery in pharma, particularly in Europe, while academic and government demand remained muted [12] - The diagnostics segment reported a 2% core revenue increase, with clinical diagnostics growing mid-single digits [13] Product Innovation - Investment in innovation led to approximately 25% year-over-year growth in new product revenue, with significant launches in bioprocessing, life sciences, and diagnostics [6][19] - The introduction of the ZenoTOF 8600 mass spectrometry system by SCIEX is noted for delivering up to 30 times increased sensitivity compared to previous platforms [2] Future Outlook - Danaher expects high single-digit growth in bioprocessing for 2026, supported by consumables, while equipment revenue is projected to improve to approximately flat for the year [16] - The company anticipates approximately $1.8 billion in respiratory revenue for 2026, assuming a typical season and stable customer testing protocols [14]

Danaher Corp (NYSE:DHR) on Wednesday reported fourth-quarter 2025 sales of $6.84 billion, up 4.5% year-over-year, beating the consensus of $6.81 billion. Core revenue increased 2.5% year-over-year, in line with the expected low single digits.The life science giant reported adjusted earnings of $2.23 per share, beating the consensus of $2.15.Rainer Blair, President and CEO, on Wednesday stated, “We delivered a strong finish to the year with better-than-expected performance across our portfolio.  We were part ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Financial Data and Key Metrics Changes - For the full year 2025, sales were $24.6 billion, with core revenue increasing by 2% and adjusted diluted net earnings per common share rising by 4.5% to $7.80 [7][8] - The adjusted operating profit margin was 28.2%, and free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [7][8] - In Q4 2025, sales reached $6.8 billion, with core revenue growth of 2.5% [11] Business Line Data and Key Metrics Changes - Core revenue in the biotechnology segment increased by 6%, while discovery and medical declined at a high single-digit rate due to prior year comparisons and funding constraints [13][14] - Bioprocessing core revenue grew high single digits, driven by strong demand for monoclonal antibodies [14][15] - In diagnostics, core revenue increased by 2%, with clinical diagnostics growing mid-single digits [18] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [12] - High growth markets saw mid-single digit increases, with solid growth outside of China, which experienced a low single-digit decline [12] Company Strategy and Development Direction - The company expects gradual end market improvements to continue, supported by a differentiated portfolio and the Danaher Business System [7][23] - Focus on innovation and new product introductions, with approximately 25% year-over-year growth in new product revenue [11][8] - Anticipation of core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the bioprocessing market, driven by robust FDA approvals and increasing demand for biologics [16][23] - The company remains cautious about the academic and government demand, which has been muted but stable [6][17] - Management highlighted the importance of a recovering biotech funding environment for the life sciences business [91][92] Other Important Information - The company has maintained a strong free cash flow generation for 34 consecutive years, exceeding a 100% conversion ratio [8] - The company is well-positioned for M&A opportunities, with a constructive environment and strong cash flow generation [64][66] Q&A Session Summary Question: Guidance for core revenue growth - Management confirmed a core revenue growth guidance of 3%-6% for 2026, with bioprocessing expected to remain strong at high single digits [27][28] Question: Bioprocessing order book and growth - The order book supports high single-digit growth for bioprocessing, with equipment orders showing sequential growth [33][34] Question: Strength in SCIEX and end market recovery - SCIEX experienced mid-single-digit growth, driven by innovation and improvement in the pharma end market [40][41] Question: Margin expectations for 2026 - Management expects margins to follow core growth, with benefits from cost actions expected to materialize in the second half of the year [42][43] Question: Biotech funding impact on life sciences - The biotech segment is sensitive to funding improvements, which could enhance order volumes [91][92] Question: Reshoring trends in bioprocessing - Management noted ongoing discussions about reshoring, indicating a potential long-term investment cycle in bioprocessing [94][95]